gremubamab(MEDI3902)在铜绿假单胞菌定植的机械通气ICU患者中的安全性、疗效与药代动力学:一项随机对照试验
EVADE(NCT02696902)是一项2期、随机、平行组、双盲、安慰剂对照研究,在欧洲、土耳其、以色列和美国开展,纳入≥18岁、机械通气、气管内铜绿假单胞菌定植且无新发肺炎的患者,1:1:1随机接受MEDI3902 500 mg、1500 mg单次静脉给药或安慰剂。因入组缓慢未达到初始样本量,共随机188例(500/1500 mg组n=16/87,安慰剂组n=85),184例接受给药构成改良意向治疗集。500 mg组因药代动力学数据显示血清浓度低而停止入组。主要终点21天内铜绿假单胞菌肺炎发生率在1500 mg组为22.4%(19/85),安慰剂组为18.1%(15/83),相对风险降低-23.7%(80%CI -83.8%至16.8%,p=0.49)。1500 mg给药后21天平均血清浓度为9.46(标准差7.91)μg/mL,80.6%(58/72)受试者浓度>1.7 μg/mL。治疗中出现的不良事件发生率组间相似。结论为gremubamab未降低铜绿假单胞菌定植机械通气患者的铜绿假单胞菌院内肺炎发生率。
要点
- 在铜绿假单胞菌定植的机械通气患者中,单次静脉gremubamab 1500 mg组21天内铜绿假单胞菌肺炎发生率为22.4%(19/85),安慰剂组为18.1%(15/83),相对风险降低-23.7%(80%CI -83.8%至16.8%,p=0.49),未达统计学显著。
- 500 mg组因药代动力学数据显示血清MEDI3902浓度低而停止入组,后续按1:1随机分配至1500 mg或安慰剂。
- 1500 mg给药后21天平均血清浓度为9.46(标准差7.91)μg/mL,80.6%(58/72)受试者浓度>1.7 μg/mL(动物模型中与结局改善相关的水平)。
- 治疗中出现的不良事件发生率组间相似。
- 研究因入组缓慢未达到初始样本量,共随机188例。
适用人群与场景
- ≥18岁、机械通气、气管内铜绿假单胞菌定植且无新发肺炎的患者。
- 研究在欧洲、土耳其、以色列和美国开展。
诊断标准与关键阈值
- 主要疗效终点为给药后21天内铜绿假单胞菌院内肺炎发生率,由独立裁定委员会判定。
处置流程与药物剂量
- MEDI3902 500 mg或1500 mg单次静脉给药,或安慰剂。
- 500 mg组因药代动力学数据显示血清浓度低而停止入组,后续受试者按1:1随机分配至1500 mg或安慰剂。
研究设计与关键结果
- EVADE(NCT02696902)为2期、随机、平行组、双盲、安慰剂对照研究;因入组缓慢未达到初始样本量,2016年4月13日至2019年10月17日共随机188例(MEDI3902 500/1500 mg组n=16/87,安慰剂组n=85),其中184例接受给药(500/1500 mg组n=16/85,安慰剂组n=83)构成改良意向治疗集。
- 主要终点:1500 mg组21天内铜绿假单胞菌肺炎发生率为22.4%(19/85),安慰剂组为18.1%(15/83),相对风险降低-23.7%(80%CI -83.8%至16.8%,p=0.49)。
- 药代动力学:1500 mg给药后21天平均血清浓度为9.46(标准差7.91)μg/mL,80.6%(58/72)受试者浓度>1.7 μg/mL。
- 安全性:治疗中出现的不良事件发生率组间相似。
证据类型、等级与局限
- 证据类型:2期随机、平行组、双盲、安慰剂对照试验。
- 局限:因入组缓慢未达到初始样本量。
对床旁实践的改变
- 作者结论:双价、双特异性单克隆抗体MEDI3902(gremubamab)未降低铜绿假单胞菌定植机械通气患者的铜绿假单胞菌院内肺炎发生率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Ventilator-associated pneumonia caused by Pseudomonas aeruginosa (PA) in hospitalised patients is associated with high mortality. The effectiveness of the bivalent, bispecific mAb MEDI3902 (gremubamab) in preventing PA nosocomial pneumonia was assessed in PA-colonised mechanically ventilated subjects.
METHODS: EVADE (NCT02696902) was a phase 2, randomised, parallel-group, double-blind, placebo-controlled study in Europe, Turkey, Israel, and the USA. Subjects ≥ 18 years old, mechanically ventilated, tracheally colonised with PA, and without new-onset pneumonia, were randomised (1:1:1) to MEDI3902 500, 1500 mg (single intravenous dose), or placebo. The primary efficacy endpoint was the incidence of nosocomial PA pneumonia through 21 days post-dose in MEDI3902 1500 mg versus placebo, determined by an independent adjudication committee.
RESULTS: Even if the initial sample size was not reached because of low recruitment, 188 subjects were randomised (MEDI3902 500/1500 mg: n = 16/87; placebo: n = 85) between 13 April 2016 and 17 October 2019. Out of these, 184 were dosed (MEDI3902 500/1500 mg: n = 16/85; placebo: n = 83), comprising the modified intent-to-treat set. Enrolment in the 500 mg arm was discontinued due to pharmacokinetic data demonstrating low MEDI3902 serum concentrations. Subsequently, enrolled subjects were randomised (1:1) to MEDI3902 1500 mg or placebo. PA pneumonia was confirmed in 22.4% (n = 19/85) of MEDI3902 1500 mg recipients and in 18.1% (n = 15/83) of placebo recipients (relative risk reduction [RRR]: - 23.7%; 80% confidence interval [CI] - 83.8%, 16.8%; p = 0.49). At 21 days post-1500 mg dose, the mean (standard deviation) serum MEDI3902 concentration was 9.46 (7.91) μg/mL, with 80.6% (n = 58/72) subjects achieving concentrations > 1.7 μg/mL, a level associated with improved outcome in animal models. Treatment-emergent adverse event incidence was similar between groups.
CONCLUSIONS: The bivalent, bispecific monoclonal antibody MEDI3902 (gremubamab) did not reduce PA nosocomial pneumonia incidence in PA-colonised mechanically ventilated subjects. Trial registration Registered on Clinicaltrials.gov ( NCT02696902 ) on 11th February 2016 and on EudraCT ( 2015-001706-34 ) on 7th March 2016.
参考来源
- Chastre J, François B, Bourgeois M, et al. Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial. Crit Care. 2022. PMID: 36380312. doi:10.1186/s13054-022-04204-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。